Search This Blog

Thursday, November 14, 2019

U.S. producer prices rise solidly; healthcare costs increasing

U.S. producer prices increased by the most in six months in October, lifted by gains in the costs of goods and services, further bolstering the Federal Reserve’s stance that it will probably not cut interest rates again in the near term.
The report from the Labor Department on Thursday showed healthcare costs accelerated last month, with the cost of outpatient care at hospitals posting its largest rise since 2009. The jump in healthcare prices mirrored gains reported in October’s consumer price index report on Wednesday.
Rising healthcare costs, if sustained, suggest inflation could trend higher, though it is not likely to become troublesome because of a moderation in the pace of rent increases.
The U.S. central bank last month cut rates for the third time this year and signaled a pause in the easing cycle that started in July when it reduced borrowing costs for the first time since 2008. Fed Chair Jerome Powell reiterated that stance in testimony before lawmakers on Wednesday.
The producer price index for final demand rose 0.4% last month, the biggest increase since April, after falling 0.3% in September. In the 12 months through October, the PPI climbed 1.1%, the smallest increase since October 2016, after advancing 1.4% in the 12 months through September. Annual producer inflation retreated as last year’s hefty gain dropped out of the calculation.
Economists polled by Reuters had forecast the PPI would rise 0.3% in October and climb 0.9% on a year-on-year basis.
Excluding the volatile food, energy and trade services components, producer prices edged up 0.1% after being unchanged in September. The so-called core PPI increased 1.5% in the 12 months through October after gaining 1.7% in the 12 months through September. Annual core PPI also slowed last month as last October’s increase dropped out of the calculation.
The data came on the heels of a report on Wednesday showing a strong rise in consumer prices in October amid large gains in healthcare costs and prices of used cars and trucks.
The Fed, which has a 2% annual inflation target, tracks the core personal consumption expenditures (PCE) price index for monetary policy. The core PCE price index rose 1.7% on a year-on-year basis in September and has undershot its target this year. October PCE price data will be published later this month.
U.S. stock index futures were trading slightly lower while the dollar .DXY was largely unchanged against a basket of currencies. Prices of U.S. Treasuries rose.

LABOR MARKET STRENGTH

Stabilizing inflation follows in the wake of fairly upbeat data on the economy, including better-than-expected job growth in October and an acceleration in services sector activity, which have eased financial market fears of a recession. There have also been hopeful signs in the 16-year trade war between the United States and China, which has pressured business investment and manufacturing.
Though another report from the Labor Department on Thursday showed the number of Americans filing claims for unemployment benefits rose to a five-month high last week, that likely does not signal a shift in labor market conditions as claims for several states were estimated because of Monday’s holiday.
Initial claims for state unemployment benefits increased 14,000 to a seasonally adjusted 225,000 for the week ended Nov. 9, the highest reading since June 22, the Labor Department said. Some of the states, including California, Pennsylvania and Virginia, did not have enough time to process the claims data because of Monday’s Veterans Day holiday, leading to them making estimates.
The four-week moving average of initial claims, considered a better measure of labor market trends as it irons out week-to-week volatility, rose only 1,750 to 217,000 last week.
Labor market strength, marked by the lowest unemployment rate in nearly 50 years, is supporting consumer spending and helping to offset some of the hit on the economy from the U.S.-China trade war.
In October, wholesale energy prices rebounded 2.8% after dropping 2.5% in September. They were boosted by a 7.3% surge in gasoline prices, which followed a 7.2% decline in September.
Gasoline accounted for nearly half of the 0.7% increase in goods prices last month. Goods prices fell 0.4% in September.
Wholesale food prices jumped 1.3% in October after rising 0.3% in September. Core goods prices were unchanged last month. They slipped 0.1% in September.
The cost of services increased 0.3% last month after decreasing 0.2% in September. Services were lifted by a 0.8% surge in trade services, which measure changes in margins received by wholesalers and retailers.

The cost of healthcare services accelerated 0.8% in October after gaining 0.3% in the prior month. The cost of hospital outpatient care increased 0.7% last month, the most since July 2009. Inpatient care prices rose 0.6%, the most since October 2018. Those healthcare costs feed into the core PCE price index.
But portfolio management fees, which also go into the calculation of the core PCE price, index fell 0.9% in October after being unchanged in September.

HDL Cholesterol Lab Test Lends New Insight into Cardiovascular Risk: Quest

A laboratory test that evaluates high-density lipoprotein (HDL) cholesterol function provides unique and novel information for assessing cardiovascular disease risk, according to data presented today (Abstract #1020) by Quest Diagnostics (NYSE: DGX) at the 2019 American Heart Association Scientific Sessions. The study is one of four the company will present at the conference, which runs November 16-18, in Philadelphia (Booth #1502).

“One in four Americans die from cardiovascular disease, but many could escape that outcome with early disease detection and preventive care,” said Jay G. Wohlgemuth, M.D., Chief Medical Officer and Senior Vice President, Research & Development and Medical, Quest Diagnostics. “Our data demonstrates the value of diagnostic insights in illuminating risks in early treatable stages in clinical and workplace populations. We are particularly encouraged by our latest findings on the ability of HDL function testing to provide insights into disease risk independent of other markers.”
HDL Function
Conventional cholesterol lab tests evaluate blood levels of HDL cholesterol (HDL-C), low-density lipoprotein (LDL) cholesterol, total cholesterol and triglycerides. A growing body of evidence suggests that the function of apolipoproteins that comprise HDL in removing cholesterol from blood vessel walls (called cholesterol efflux capacity or CEC) may be a better marker of disease risk than HDL-C. However, assessing CEC has traditionally involved sophisticated laboratory cell culturing, limiting its use in medical practice.
A team of experts from Quest Diagnostics and its Cleveland HeartLab cardiometabolic center of excellence developed a high-throughput laboratory method that evaluates certain apolipoproteins to establish a score predictive of CEC. The team correlated the test against other established markers, including HDL, LDL and insulin blood levels, in 341 individuals. The analysis found that the test provides “weak, but significant correlation” with markers associated with cardiovascular risk, and thereby provides “novel and unique information above what current tests offer to define a patient’s risk.”
“Too often, heart disease fails detection until a major cardiac event. While traditional methods of testing can identify risk in many patients, they may not always provide the full story,” said Marc Penn, MD, PhD, FACC, Founder, Cleveland Heart Lab and Medical Director, Cardiometabolic Endocrine Division, Quest Diagnostics. “The present study provides tantalizing evidence that HDL function testing will complement other methods of evaluating an individual’s cardiovascular health, enhancing risk detection and patient management.”
The data follows publication of a study earlier this year in the Journal of American College of Cardiology by researchers from Cleveland HeartLab,  Massachusetts General Hospital, Harvard Medical School and other prominent research institutions that found, among individuals with coronary artery disease, the HDL function test may be independently associated with cardiovascular death in individuals with coronary artery disease.
The HDL Function test is expected to be available nationally in 2020. It will be the first significant innovation to emerge from Cleveland HeartLab since the company was acquired by Quest Diagnostics in December 2017.

Bayer to Work With Dewpoint Therapeutics to Develop New Therapies

Bayer AG (BAYN.XE) said Thursday that it is investing up to $100 million to research new treatments for cardiovascular and gynecological diseases with U.S. biotech Dewpoint Therapeutics.
The two companies signed an option, research and license agreement, Bayer said. Under the terms of the deal it will use Dewpoint’s biomolecular condensates platform to drive research into the disease areas.
Germany’s Bayer also said that it will have the option to exclusively license new therapy candidates developed from the research activities.

Glaxo Wants to Look Inside Your Gut to Discover New Vaccines

GlaxoSmithKline Plc is exploring the trillions of microbes that inhabit the gut in pursuit of novel ways to prevent some of the world’s most common ailments.
The U.K. pharma giant is teaming up with Viome, a company backed by venture capitalist Vinod Khosla and Salesforce.com Inc. co-founder Marc Benioff, to gain a deeper understanding of the universe of bacteria that dwell in the digestive tract and the role they play in the body’s immune system.
relates to Glaxo Wants to Look Inside Your Gut to Discover New Vaccines
The Viome app.
The collaboration is the latest sign of interest in an exciting but unproven new frontier of drug development. Glaxo rival AstraZeneca Plc joined with Seres Therapeutics Inc. earlier this year to study microbiome-based approaches to boost the efficacy of cancer immune therapies, while others take aim at illnesses from obesity to depression, seeking to turn fresh discoveries into commercial products. For Glaxo, the goal is to find novel vaccines.
The field wasn’t “mature enough to really consider something serious” until recently, Emmanuel Hanon, the research and development head of Glaxo’s vaccines business, said in an interview. “The science behind the microbiome has evolved amazingly in recent years, even months.”
Billionaire philanthropist Bill Gates wrote in an editorial last month that new insights into gut bacteria could help prevent malnutrition, obesity, asthma, allergies as well as some auto-immune diseases.
The Glaxo deal, focused on chronic diseases, will give the drugmaker access to technology licensed from Los Alamos National Laboratory in New Mexico as well as data from tailored research projects. The Seattle-based company examines the collection of gut organisms based on stool samples. To do so, it uses an artificial intelligence system nicknamed Vie to analyze how they function and what their genes tell them to do. Neither Glaxo nor Viome agreed to provide financial terms of the two-year agreement.

Data Boom

Declining costs to sequence RNA and advances in artificial intelligence could allow Viome to crunch huge amounts of information from millions of people in a way that was never possible before, said Naveen Jain, the company’s founder.
Kairos Society Global Summit At One World Observatory
Naveen Jain
Photographer: Brad Barket/Getty Images for Kairos Society
Viome’s stool tests try to assess whether the body is turning food into nutrients or harmful toxins, and then delivers personalized recommendations to clients. Jain aims to boost the company’s customer base to 1 million by the end of next year from more than 100,000 now, driven by distribution deals with food companies he declined to name.
Using microbiome data as a way to potentially come up with new vaccines “even half a decade ago would have been a completely bizarre concept,” said Jain, who has started other companies including InfoSpace, an early web-services provider that became a symbol of the dot-com boom and bust. “Think about how far we’ve come. We have a completely new way of looking at the human body.”
The fledgling field has already experienced some significant setbacks. San Francisco-based uBiome, which allowed consumers to monitor their gut microbes, filed for bankruptcy protection in September following a government investigation into its billing practices.
That hasn’t deterred investors and pharma companies. Merck & Co. last month reached an agreement with 4D Pharma Plc to gain insights into the microbiome with the goal of creating new vaccines. Takeda Pharmaceutical Co. also signed a deal last year with Enterome SA, a biotech firm developing medicines at the crossroads between the immune system and the microbiome.
Hanon wouldn’t identify specific diseases the partners will focus on. The Viome collaboration is part of Glaxo’s plans to come up with the next generation of vaccines. The company wants to expand in therapeutic vaccines, used after an infection occurs, and to speed up the development of new shots.

FDA grants RPD status to Anavex 2-73

The FDA grants Rare Pediatric Disease (RPD) designation to Anavex Life Sciences’ (NASDAQ:AVXL) lead drug Anavex 2-73 (blarcamesine) for the treatment of a rare inherited neurological disorder called Rett syndrome that affects mostly girls.
RPD Designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party.
Phase 2 studies are in process.
Shares up 7% premarket on light volume.

FDA panel thumbs down on Boehringer-Lilly empagliflozin for Type 1 Diabetes

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 14 – 2 that the benefits of Boehringer Ingelheim and Eli Lilly’s (NYSE:LLY) SGLT2 inhibitor empagliflozin do not outweigh the risks as an adjunct to insulin for adults with type 1 diabetes (T1D).
Empagliflozin, branded as Jardiance, was approved in the U.S. in August 2014 for adults with type 2 diabetes (T2D).

FDA accepts AstraZeneca-Merck selumetinib marketing application

The FDA accepts under Priority Review a marketing application seeking approval of AstraZeneca (NYSE:AZN) and collaboration partner Merck’s (NYSE:MRK) MEK 1/2 inhibitor selumetinib for the treatment of pediatric patients at least three years old with neurofibromatosis type 1 (NF1) and symptomatic inoperable plexiform neurofibromas (tumors that are a common complication of NF1).
The agency’s action date is in Q2 2020.
NF1 is a rare inherited disorder characterized by changes in skin coloring and tumor growth along nerves in the skin, brain and other parts of the body.